The appropriate use of antenatal corticosteroids improves neonatal outcomes, including decreased severity and/or frequency of respiratory distress syndrome (RDS), intracranial hemorrhage, necrotizing enterocolitis and death. Antenatal corticosteroids, when appropriate, are administered in a clinical setting where patients are at risk for preterm delivery within 7 days, irrespective of membrane status and fetal number.
Clinical Actions:
Risk of preterm delivery within 7 days
Between 24w0d to 33w6d – ‘Recommended’
Single course of corticosteroids
Between 22w0d and 23w6d – ‘May be Considered’
23w0d to 23w6d
Single course of corticosteroids
22w0d to 22w6d
Single course of corticosteroids
Note: ACOG and SMFM revised recommendation states
Antenatal corticosteroids may be considered at 22 0/7 weeks to 22 6/7 weeks of gestation if neonatal resuscitation is planned and after appropriate counseling
Some families may choose to forgo resuscitation and support after appropriate counseling
Between 20w0d and 21w6d – ‘Not Recommended’
Antenatal corticosteroids are not recommended due to lack of data suggesting benefit
Late preterm (34w0d – 36w6d)
ACOG
If no previous corticosteroids
Single course of betamethasone
Not indicated in women diagnosed with clinical chorioamnionitis
SMFM
Single course of betamethasone in specific populations
Population included in ALPS trial: Recommended
Nonanomalous singleton gestation
High risk for preterm delivery (medically indicated or spontaneous)
No prior antenatal steroids
Select populations not in the original ALPS trial: Suggest consideration for use in the following clinical scenarios
Multiple gestations reduced to a singleton gestation ≥14w0d
Fetal anomalies
Expected to deliver in less than 12 hours
Low likelihood of delivery <37 weeks: Recommend against
Pregestational diabetes: Recommend against due to risk for worsening neonatal hypoglycemia
Repeat or Rescue Courses
Regularly scheduled repeat courses or serial (> 2) courses
Not recommended
If a patient has received one prior course of corticosteroids > 14 days ago, is less than 34w0d gestation and is at risk of preterm delivery within 7 days
a single repeat course of corticosteroids should be considered (change from previous ‘may’)
Rescue course corticosteroids could be provided as early as 7 days from the prior dose, if indicated by the clinical scenario (based on Cochrane meta-analysis)
Preterm prelabor rupture of membranes (PPROM)
There is insufficient evidence to make a recommendation for or against repeat or rescue courses
Dose and Regimen: give first dose even if 2nd dose unlikely
ACOG defines cervical insufficiency as “the inability of the uterine cervix to retain a pregnancy in the absence of the signs and symptoms of clinical contractions, or labor, or both in the second trimester.” In addition, ACOG separates out indication for cerclage in to 3 categories
History: ≥1 of the following
Second trimester pregnancy losses related to painless cervical dilation and no history of labor or abruption
Previous second trimester cerclage for painless cervical dilation
Physical Examination: Also known as ‘physical examination–indicated cerclage’, ‘rescue cerclage’ and ’emergency cerclage’
Patient presents with painless second trimester cervical dilation
Ultrasound: Cervical length shortening and history of preterm birth
Singleton pregnancy
Prior spontaneous preterm birth (<34 weeks)
Cervical length: <25 mm (at <24 weeks)
Timing of Cerclage Placement
History-indicated cerclage
Place between 12 and 14 weeks after confirmation of pregnancy viability
Ultrasound or exam-indicated cerclage
May be placed prior to 23 weeks
Risk Factors
Prior PTB
Repeated cervical dilation
Cervical procedures (including cone and LEEP)
Cervical laceration
Urogenital abnormalities
SYNOPSIS:
Clinically, cervical insufficiency is painless dilation and recurrent mid-trimester losses without signs of preterm labor (PTL), PPROM, or infection. Patient history may include superimposed symptoms (i.e. bleeding, pressure), therefore a judicious review of records is advised. Those with a history of prior preterm birth can benefit from cervical length screening to appropriate guide selected patients for cerclage.
KEY POINTS:
Ultrasound Indicated Cerclage with Prior History of Preterm Birth <34 weeks and cervical length <25 mm before 24 weeks
Cerclage associated with
Decreased preterm birth
Improved neonatal outcomes
No history of preterm birth
Cerclage for short cervix at <24 weeks has not been associated with improved preterm birth rates
Evidence from research studies
There is no demonstrated difference in efficacy of McDonald versus Shirodkar techniques
‘Emergency’ Cerclage (Exam indicated)
There is literature, including a meta-analysis (Obstet Gynecol, 2015), to support ’emergency’ or ‘rescue’ cerclage
Neonatal survival
Cerclage: 71% survival
No cerclage: 43% survival
Relative risk 1.65 (95% CI 1.19 to 2.28)
Prolongation of pregnancy
Mean difference: 33.98 days (95% CI, 17.88 to 50.08)
Authors note significant limitations including quality of data and only 1 RCT included
After clinical examination to rule out uterine activity, or intraamniotic infection, or both, physical examination-indicated cerclage placement (if technically feasible) in patients with singleton gestations who have cervical change of the internal os may be beneficial
Additional Interventions
Evidence does not support use of the following after cerclage placement
Serial cervical length measurements
Antibiotics
Prophylactic tocolysis
Cerclage Removal
Remove transvaginal McDonald cerclage at 36 to 37 weeks
Cesarean delivery planned for ≥39 weeks
May be removed at time of delivery
Consider possibility of spontaneous labor between 37 and 39 weeks
McDonald cerclage may be removed in the office
PPROM
Removal or retention “is reasonable”
Prolonged antibiotic prophylaxis >7 days not recommended if suture is retained
Preterm labor
Diagnosis may be more difficult with cerclage in place
Routine management of preterm labor should be followed for patients with symptomatic preterm labor
If cervical change, painful contractions, or vaginal bleeding progress, cerclage removal is recommended
Updated Outcomes Data for Neonates less than 500 Grams at Birth
BACKGROUND AND PURPOSE:
There is limited data on extremely low birthweight newborns
Bashir et al. (Am J Perinatol, 2017) describe survival, short-term, and long-term morbidities of neonates < 500g
METHODS:
Retrospective cohort study
Neonatal Follow-Up Program (NFUP) at British Columbia’s Women’s Hospital and Health Centre (BCWH)
Prospectively enrolls neonates with birth weight ≤ 800 g
Conducts multidisciplinary neurodevelopmental assessments at ages 4, 8, and 18 months corrected age (CA), and at 3 and 4.5 years chronological age since 1983
The first survivor with birth weight < 500 g was born in 1985
Primary objectives
Calculated survival and morbidity rates as well as neurodevelopmental impairment rates at 4.5 years of neonates < 500g
Secondary objective
Compare outcomes of small for gestational age (SGA) infants against entire cohort where <500 g is appropriate for gestational age
RESULTS:
Data from 549 neonates with birth weight < 500g was collected
Among liveborns
180 (83%) died in the delivery room
17 (8%) died in the NICU
21 (10%) survived
Among all births, 3.8% (21/549) survived
Of NICU survivors
Median birth weight was 460 g
Median gestational age was 25.9 weeks (range: 22.6-30.3 weeks)
71% were inborn | 50% male | 75% were SGA
20% were a twin or multiple
Complications – Leading Short Term Morbidities
Branchopulmonary dysplasia (91%)
Culture proven sepsis (50%)
Retinopathy of prematurity (41%)
Severe brain injury (22%)
Complications – Long Term Morbidities
27% had no long-term impairment
23% had one, 23% had two, 18% had three, and 9% had four impairments in motor, cognitive, vision, and/or hearing domains
At 4.5 years
29% had visual impairment
10% wore hearing aids
50% had an IQ <70
18% cerebral palsy
68% had low motor scores
CONCLUSION:
Approximately 4% of births <500 g survived, with all survivors having short-term morbidities
27% of neonates survived without long-term impairment
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site
